Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with Microtransplantation in AML
NCT02255162Phase 1Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenalidomide in acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose of lenalidomide after microtransplantation at 42 Days. Started Jan 2015; status: terminated.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02255162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02255162.